“Through the MedTech Funding Mandate, NHS England aims to ensure all parts of the healthcare system are aware of the benefits of certain medical products and able to access them.
Officials sought feedback on the idea late in 2019 with a view to starting the initiative in April 2020 but the need to focus healthcare resources on COVID-19 delayed the go-live date. Now, NHS England has published details of the consultation responses and set out its plans for the delayed start of the initiative.
Originally, NHS England planned to include three products in the scheme in its first year, namely Quidel and Roche’s placental growth factor-based preeclampsia tests, Interrad Medical’s SecurAcath for securing percutaneous catheters and HeartFlow’s eponymous device for estimating fractional flow reserve. NHS England estimated including the products in the scheme could save the health system £20 million ($27 million) over five years.”